Erik Hertervig

3.2k total citations · 1 hit paper
47 papers, 2.0k citations indexed

About

Erik Hertervig is a scholar working on Epidemiology, Genetics and Molecular Biology. According to data from OpenAlex, Erik Hertervig has authored 47 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Epidemiology, 24 papers in Genetics and 15 papers in Molecular Biology. Recurrent topics in Erik Hertervig's work include Inflammatory Bowel Disease (24 papers), Microscopic Colitis (24 papers) and Sphingolipid Metabolism and Signaling (11 papers). Erik Hertervig is often cited by papers focused on Inflammatory Bowel Disease (24 papers), Microscopic Colitis (24 papers) and Sphingolipid Metabolism and Signaling (11 papers). Erik Hertervig collaborates with scholars based in Sweden, Denmark and United States. Erik Hertervig's co-authors include Per Karlén, Anders Magnuson, Ingalill Friis–Liby, Per M. Hellström, M. Vilien, Hans Verbaan, Christer Grännö, Lars Blomquist, Magnus Ström and Gunnar Järnerot and has published in prestigious journals such as Gastroenterology, American Journal of Clinical Nutrition and Cancer.

In The Last Decade

Erik Hertervig

47 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study

2005 789 citations Gunnar Järnerot, Erik Hertervig et al. Gastroenterology profile →

Peers

Countries citing papers authored by Erik Hertervig

Since Specialization

Citations

This map shows the geographic impact of Erik Hertervig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Hertervig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Hertervig more than expected).

Fields of papers citing papers by Erik Hertervig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Hertervig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Hertervig. The network helps show where Erik Hertervig may publish in the future.

Co-authorship network of co-authors of Erik Hertervig

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Hertervig. A scholar is included among the top collaborators of Erik Hertervig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Hertervig. Erik Hertervig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Longitudinal Post-authorization Safety Study of Golimumab in Treatment of Ulcerative Colitis: A Cohort Study in Denmark and Sweden, 2013–2021 2025 ·Drug Safety ·Annette Kjær Ersbøll, Zhiping Huang, Deanna Hill, (unknown), Vibeke Andersen, Kristian Bolin, (unknown), (unknown), (unknown), Erik Hertervig, Lila Kallio, (unknown), (unknown), Alexis A. Krumme, James D. Lewis, (unknown), Niels Qvist, Lau Caspar Thygesen, (unknown), Anders Green	1
2	Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study 2023 ·Therapeutic Advances in Gastroenterology ·(unknown), Carl Eriksson, (unknown), (unknown), Per Karlén, Olof Grip, Charlotte Söderman, Sven Almér, Erik Hertervig, Jan Marsal, (unknown), (unknown), Hans Strid, (unknown), Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson	4
3	OP02 Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn’s disease patients stopping infliximab 2023 ·Journal of Crohn s and Colitis ·Nicolas Pierre, Vân Anh Huynh‐Thu, Dominique Baiwir, Gabriel Mazzucchelli, (unknown), (unknown), Gauthier Eppe, David Laharie, Jack Satsangi, J F Colombel, Erik Hertervig, Marie‐Alice Meuwis, (unknown)	1
4	O47 Treatment de-escalation in crohn’s disease patients in remission under infliximab and immunosuppressant therapy: the SPARE trial 2022 ·Oral Presentations ·Édouard Louis, Matthieu Resche‐Rigon, David Laharie, Nik S. Ding, Peter M. Irving, Christopher A Lamb, (unknown), Jean‐Frédéric Colombel, Erik Hertervig, Jack Satsangi	1
5	Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG 2021 ·Scandinavian Journal of Gastroenterology ·Carl Eriksson, (unknown), Lina Vigren, (unknown), Anders Kärnell, Henrik Hjortswang, Daniel Bergemalm, (unknown), Sven Almér, Erik Hertervig, Per Karlén, Hans Strid, Jonas Halfvarson	6
6	Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study 2021 ·Therapeutic Advances in Gastroenterology ·Carl Eriksson, (unknown), (unknown), Ruzan Udumyan, Per Karlén, Olof Grip, Charlotte Söderman, Sven Almér, Erik Hertervig, Jan Marsal, (unknown), (unknown), (unknown), Hans Strid, (unknown), (unknown), Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson, (unknown)	19
7	The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn’s Disease 2019 ·Journal of Crohn s and Colitis ·Kristian Bolin, Erik Hertervig, Édouard Louis	10
8	Changes of activity and isoforms of alkaline sphingomyelinase (nucleotide pyrophosphatase phosphodiesterase 7) in bile from patients undergoing endoscopic retrograde cholangiopancreatography 2014 ·BMC Gastroenterology ·Rui‐Dong Duan, Ulf Hindorf, Yajun Cheng, (unknown), (unknown), Erik Hertervig, Åke Nilsson	6
9	Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients 2013 ·Alimentary Pharmacology & Therapeutics ·(unknown), Anders Magnuson, Jan Björk, Cecilia Benoni, Sven Almér, Ingalill Friis–Liby, Erik Hertervig, (unknown), Per Karlén, Anders Eriksson, G. Midhagen, Marie Carlson, Annika Lapidus, Jonas Halfvarson, Curt Tysk	64
10	Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3‐year follow‐up of the Swedish‐Danish controlled infliximab study 2010 ·Alimentary Pharmacology & Therapeutics ·(unknown), G Järnerot, Erik Hertervig, Ingalill Friis–Liby, L. Blomquist, Per Karlén, Christer Grännö, M. Vilien, Morten B. Strøm, Hans Verbaan, Per M. Hellström, Anders Magnuson, Jonas Halfvarson, Curt Tysk	133
11	Characterization of a novel sequence variant, TPMT28, in the human thiopurine methyltransferase gene 2010 ·Pharmacogenetics and Genomics* ·Malin Lindqvist Appell, (unknown), Curt Peterson, Erik Hertervig, Lars‐Göran Mårtensson	24
12	Colectomy after rescue therapy for intravenous-steroid resistant acute ulcerative colitis : a 3-year follow-up study of the Swedish-Danish infliximab/placebo trial 2008 ·Gut ·Anders Gustavsson, Gunnar Järnerot, Erik Hertervig, Ingalill Friis–Liby, L. Blomquist, Per Karlén, Christer Grännö, M. Vilien, (unknown), Hans Verbaan, Per M. Hellström, Jonas Halfvarson, Anders Magnuson, Curt Tysk	4
13	A 2-year follow-up of the swedish-danish Infliximab/Placebo trial in steroid resistant acute ulcerative colitis 2007 ·Gastroenterology ·Anders Gustavsson, (unknown), Erik Hertervig, (unknown), Lars Blomquist, Per Karlén, Christer Grännö, M. Vilien, Magnus Ström, (unknown), Hans Verbaan, Per M. Hellström, Jonas Halfvarson, Anders Magnuson, Curt Tysk	14
14	Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity 2004 ·Pharmacogenetics ·Malin Lindqvist, Sofie Haglund, Sven Almér, Curt Peterson, (unknown), Erik Hertervig, (unknown), (unknown)	65
15	Purified intestinal alkaline sphingomyelinase inhibits proliferation without inducing apoptosis in HT-29 colon carcinoma cells 2003 ·Journal of Cancer Research and Clinical Oncology ·Erik Hertervig, (unknown), Yajun Cheng, Rui‐Dong Duan	36
16	Reduction in alkaline sphingomyelinase in colorectal tumorigenesis is not related to the APC gene mutation 2003 ·International Journal of Colorectal Disease ·Erik Hertervig, Åke Nilsson, Mef Nilbert, Rui‐Dong Duan	14
17	Chronic Colitis Is Associated With a Reduction of Mucosal Alkaline Sphingomyelinase Activity 2002 ·Inflammatory Bowel Diseases ·Urban Sjöqvist, Erik Hertervig, Åke Nilsson, Rui‐Dong Duan, Åke Öst, Bernhard Tribukait, Robert Löfberg	60
18	Familial adenomatous polyposis is associated with a marked decrease in alkaline sphingomyelinase activity: A key factor to the unrestrained cell proliferation? 1999 ·British Journal of Cancer ·Erik Hertervig, (unknown), Jan Björk, (unknown), (unknown)	56
19	Distribution of alkaline sphingomyelinase activity in human beings and animals 1996 ·Digestive Diseases and Sciences ·Rong Duan, Erik Hertervig, (unknown), Truls Hauge, Berit Sternby, Jan Lillienau, Aijaz Farooqi, Å Nilsson	86
20	The Expression of Glutathione Transferase μ in Patients with Inflammatory Bowel Disease 1994 ·Scandinavian Journal of Gastroenterology ·Erik Hertervig, Anna-Lena Nilsson, Janeric Seidegård	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact